Introduction
In 1990 the American College of Rheumatology (ACR) established criteria for the diagnosis of fibromyalgia (Wolfe et al., 1990) , and more recently new criteria have been proposed (Wolfe et al., 2010 (Wolfe et al., , 2011 . However, the absence of anatomic pathological lesions and of biohumoral abnormalities, demonstrated with classical instrumental methods, has led to considerable difficulties in diagnosis. Until now, many attempts have been made to search for biomarkers in fibromyalgia, but at present no specific markers have been found . The problem lies in the presence of too many data, often controversial, rather than in a lack of data. We will discuss methods that are state of the art in searching for biomarkers in fibromyalgia. Furthermore, we will focus on the contribution that proteomics can give in the diagnosis of the disease on the basis of the study we carried out on human whole saliva of patients affected by fibromyalgia.
Genetic markers
The presence of fibromyalgia in family clusters and many studies support the idea that genetic factors may predispose to fibromyalgia in combination with environmental triggers such as trauma, infections or emotional stress. The principal gene polymorphisms supposed to be a risk factor for fibromyalgia are those implicated in mood disorders but results are often controversial. These candidate genes include the serotonin transporter (5-HTT), the serotonin 2A (5-HT2A) receptor, catechol-O-methyltransferase (COMT) and the dopamine receptor. Offenbaecher and colleagues were the first to analyze the genotypes of the serotonin transporter promoter locus (5HTTLPR) in patients with fibromyalgia. They found that the S/S genotype of 5-HTT occurred more frequently in fibromyalgia patients than in healthy controls. This association is interesting considering that 5-HTT is involved in many conditions that are either risk factors for -or frequent concomitants to-fibromyalgia, such as anxiety, Bipolar Disorder, Psychosis, attention deficit hyperactivity disorder, and Major Depressive Disorder (Maletic & Raison, 2009 ). addition, HH genotypes in patients were significantly lower than in the control group (Gürsoy et al., 2003) . It was concluded that COMT polymorphism is of potential pharmacological importance concerning individual differences in the metabolism of catechol drugs. In addition, it may also be involved in the pathogenesis and treatment of fibromyalgia through adrenergic mechanisms as well as in the genetic predisposition to fibromyalgia (Gürsoy et al., 2003) . Matsuda et al. confirmed these results in the Brazilian population (Matsuda et al., 2010) showing that the LL genotype was more frequently found among fibromyalgia patients. On the other hand, Tander and subsequently Lee didn't find any associations between the COMT gene and fibromyalgia Tander et al., 2008) . Finally, some studies have established a connection between fibromyalgia and the dopaminergic system. Dopaminergic neurotransmission was found to be altered in fibromyalgia patients by Malt and colleagues. They suggested an increased sensitivity or density of dopamine D 2 receptors in fibromyalgia patients (Malt et al., 2003) . Buskila and collaborators demonstrated an association between fibromyalgia and the 7-repeat allele in exon III of the D 4 receptor gene, specifically that the frequency of this polymorphism was significantly lower in people with fibromyalgia (Buskila et al., 2004) . More recently, Treister et al. found an association between the dopamine transporter gene (DAT-1) polymorphism and cold pain tolerance. Their results, together with the known function of the investigated candidate gene polymorphisms, suggest that low dopaminergic activity can be associated with high pain sensitivity (Treister et al., 2009 ). However, Ablin and co-workers, investigating an association between fibromyalgia and DAT1, found no significant association between fibromyalgia and the genetic marker (Ablin et al., 2009 In conclusion, all these genetic studies support a role for the polymorphism of genes of the serotoninergic, catecholaminergic and dopaminergic systems in the etiopathogenesis of fibromyalgia. These polymorphism are often associated with psychiatric disorders, thereby they could be related to psychiatric comorbidities rather than to sole fibromyalgia. Furthermore, genetic results are often controversial, and no specific candidate gene has been closely connected with fibromyalgia.
Serologic markers
There is a great interest in using a simple blood test to diagnose fibromyalgia. Thus, many attempts have been carried out in order to identify specific serologic markers. These results, as well as those of genetic studies, are often conflicting and, at present, no clinical test has been validated yet.
Autoantibodies
Autoimmunity has a central role in pathogenesis of many rheumatic diseases while fibromyalgia is generally considered to be a non-autoimmune disease. Nevertheless, a broad spectrum of autoantibodies has been widely investigated in the sera from patients. The studies have often generated controversial data, and the proposed antibodies don't have diagnostic relevance yet. The association between the antipolymer antibody (APA) and fibromyalgia was evaluated because APAs were found in the sera of women with silicone breast implants presenting fibromyalgia-like symptoms (Wolfe, 1999) . In addition, Wilson et al. found a higher prevalence of APAs (67%) in fibromyalgia patients in the USA population (Wilson et al., 1999) . Furthermore, a Danish study showed that fibromyalgia patients tended to have slightly higher APA levels than controls when adjusted for symptom severity (Jensen et al., 2004) . However, these results were not confirmed in the Italian population by Bazzichi and colleagues . Instead, they found a lower percentage of APA seropositivity (23%) in fibromyalgia patients. A correlation between the APA and pain and fatigue severity in fibromyalgia was also proposed by Sarzi-Puttini et al. because the APA test did not distinguish this group from the controls, but instead a positive APA test prevalence increased with less severe pain or fatigue (Sarzi-Puttini et al., 2008) . A more recent study evaluated the APA concentration in the serum of patients with fibromyalgia, patients with tension-type headache, and healthy controls. APAs were detected in only 17.6% of fibromyalgia patients confirming the lack of diagnostic relevance of the APA . Two other autoantibodies, the anti-68/48 kDa and the anti-45 kDa, have been described as possible markers for certain clinical subsets of primary fibromyalgia and chronic fatigue syndrome, and for secondary fibromyalgia/psychiatric disorders, respectively (Nishikai et al., 2001) . Antiserotonin, antiganglioside and antiphospholipid antibodies have been shown to be higher in fibromyalgia patients as well as in those with chronic fatigue syndrome, supporting the concept that fibromyalgia and chronic fatigue syndrome may belong to the same clinical entity and may manifest themselves as 'psycho-neuro-endocrinological autoimmune diseases' (Klein & Berg, 1995) . A different group, evaluating the prevalence and potential diagnostic relevance of antiserotonin, antithromboplastin and antiganglioside in patients with fibromyalgia, confirmed an elevated prevalence of antibodies against serotonin and thromboplastin, but they concluded that the measurement of these antibodies had no diagnostic relevance (Werle et al., 2001) . Another important research field is thyroid autoimmunity. Bazzichi and collaborators found that autoimmune thyroiditis is present in an elevated percentage of fibromyalgia patients. In particular, 41% of these patients had at least one thyroid antibody, a percentage that was twice the value of the control group's . More recently, they confirmed this significant association between thyroid autoimmunity and fibromyalgia . Pamuk & Cakir also found a higher frequency of thyroid autoimmunity in fibromyalgia patients than in the control group, while the frequency was similar between fibromyalgia patients and the rheumatoid arthritis group (Pamuk & Cakir, 2007) . Essentially, the association between rheumatic and thyroid disorders have long been known, the most common being the associations with rheumatoid arthritis, Sjögren's syndrome, and systemic lupus erythematosus. Therefore, at present, the proposed antibodies have not been validated yet as being strong, useful diagnostic biomarkers for fibromyalgia and further studies are necessary to reach a research end point.
Neuropeptides
Neuropeptide Y is a neurotransmitter released mainly by sympathetic neurons in the autonomic nervous system, and it has a complex role in mediating analgesia and hyperalgesia. Thus, Neuropeptide Y has been shown, to both reduce and cause pain. Crofford and colleagues were the first to measure plasma Neuropeptide Y levels in fibromyalgia patients and they found that it was significantly lower in fibromyalgia patients than in normal subjects (Crofford et al., 1994) . These results are inconsistent with subsequent findings from Anderberg who found significantly elevated plasma Neuropeptide Y levels in fibromyalgia patients compared with the healthy subjects (Anderberg et al, 1999) . Furthermore, serum Neuropeptide Y levels have been shown to be significantly higher in fibromyalgia subjects, compared with healthy controls, by two different groups (Di Franco et al., 2009; Iannuccelli et al., 2010) . Substance P is another neuropeptide extensively studied in fibromyalgia patients. Substance P is released in the cerebral spinal fluid when axons are stimulated. An increase in substance P levels in the cerebral spinal fluid can be related to an increase of pain neurotransmitters in the spinal cord. Two studies from two different groups have demonstrated significantly elevated substance P levels in cerebral spinal fluid of fibromyalgia patients (Russell et al., 1994; Vaerøy et al., 1988 ) but levels of substance P determined in cerebral spinal fluid of patients with chronic fatigue syndrome were within normal range (Evengard et al., 1998) . It was proposed that substance P in mice produces disturbances in sleep (Andersen et al., 2006) . Subsequently, it is likely that the high levels of substance P found in fibromyalgia patients may be one of the causes of sleep dysfunction. Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family, which also includes the nerve growth factor. BDNF has a wide range of biological activities and is produced by different immune and structural cells (Iughetti et al., 2011) . BDNF seems to have a role in Major Depressive Disorder, schizophrenia, and eating disorders such as bulimia and anorexia nervosa, Parkinson's and Alzheimer's diseases, and epileptic and psychogenic nonepileptic seizures (Iughetti et al., 2011) . In addition, BDNF is a mediator of pain in the peripheral nerve system, and some findings have also suggested an involvement of BDNF in pain syndrome (Laske et al., 2006) . On the basis of this evidence, Laske and collaborators were the first to evaluate BDNF serum concentrations in fibromyalgia patients, and they found that levels significantly increased compared with healthy controls (Laske et al., 2006) . Two different groups found significantly higher levels of BDNF in plasma and in the cerebral spinal fluid of fibromyalgia patients than in controls, indicating an involvement of BDNF in the pathophysiology of fibromyalgia (Haas et al., 2010; Sarchielli et al., 2007) . The excitatory neurotransmitter glutamate is known to function in pain neuropathways, and it is suspected to play a role in the pathophysiology of fibromyalgia. This hypothesis is supported by different studies. Harris and collaborators found a correlation between changing levels of insular glutamate and changes in pain in patients with fibromyalgia using proton magnetic resonance spectroscopy and functional magnetic resonance imaging (Harris et al., 2008) . Subsequently, they extended these findings by investigating the relationship between insular glutamate and combined glutamate/glutamine in individuals with fibromyalgia and pain free controls (Harris et al., 2009) . They concluded that enhanced glutamatergic neurotransmission within the posterior insula is a potential pathologic factor in fibromyalgia. In a pilot study, Fayed and colleagues compared three different magnetic resonance imaging examination methods for the diagnosis of fibromyalgia: magnetic resonance spectroscopy, diffusion-weighted imaging, and diffusion-tensor imaging. One of the principal findings was the increase in the combined glutamate+glutamine levels, and glutamate+glutamine/creatine ratio, in the posterior gyrus in patients with fibromyalgia compared with controls (Fayed et al., 2010) . Another group used magnetic resonance spectroscopy techniques to study brain metabolites in the amygdala, thalami, and prefrontal cortex of these women. Patients with fibromyalgia showed higher levels of glutamate compounds in the right amygdala than did healthy controls, and pain was related to increased glutamate levels in the left thalamus (Valdés et al., 2010) . These findings have implications for future therapies directed against glutamate receptors, but further studies are desirable to confirm whether these findings are observed in other functional pain syndromes.
Inflammation
Since fibromyalgia is characterised by widespread pain, and the origin of pain is inflammation, many studies have focused on the inflammatory hypothesis for fibromyalgia, although fibromyalgia is generally regarded as a non-inflammatory disease. Special attention has been paid on circulating pro-inflammatory cytokines as possible markers in fibromyalgia patients. A connection between the pathogenesis of fibromyalgia and cytokines was suspected when in 1988, after being treated with IL-2 or IFN-, patients with malignant melanoma, renal cell carcinoma, and hairy cell leukaemia showed fibromyalgia-like symptoms such as myalgias, arthralgias, cognitive impairment, and painful tender points (Wallace et al., 1988 , as cited in Di . Therefore, cytokines have been suggested to be involved in the fibromyalgia syndrome, but results often appear to be controversial, especially because increases, reductions, and no significant changes have been reported. Levels of IL-10, an anti-inflammatory cytokine, were studied by four different groups with different findings. Wallace and Amel Kashipaz didn't find alterations in IL-10 levels, while Bazzichi and co-workers found an increase in plasma levels, and Uçeyler found a reduction (Amel Kashipaz et al., 2003; Uçeyler et al., 2006; Wallace et al., 2001 ).
IL-8, a pro-inflammatory cytokine, has been consistently demonstrated to be increased in patients with fibromyalgia. Bearing in mind that IL-8 promotes sympathetic pain, it may play an important role in the occurrence of pain in fibromyalgia. If validated in further studies, the IL-8 expression pattern might help in the diagnosis of fibromyalgia and in the appropriate treatment approach. 
Proteomic markers
In the last few years, it has become widely recognized that the genome represents only the first layer of complexity. Biological functions rely on a dynamic population of proteins, and the characterisation of the proteins can reveal posttranslational modifications (e.g., phosphorylation, glycosylation, and methylation), and give insight into protein-protein interactions and functions. For these reasons, there is an increasing interest in the field of proteomics wich is the identification of proteins contained in biological samples such as body fluids and tissue extracts. In 2005 Baraniuk and collaborators analyzed the cerebral spinal fluid of patients with chronic fatigue syndrome by quadrupole-time-of flight mass spectrometry, compared chronic fatigue syndrome with Persian Gulf War Illness and fibromyalgia, and concluded that the three proteomes overlapped (Baraniuk et al., 2005) . Recently, we carried out a study on human whole saliva of patients affected by fibromyalgia. The aim was to identify the protein content of whole saliva and to determine the quantitative or qualitative differences between fibromyalgia patients and healthy subjects. We expected to find multiple biomarkers rather than a single one because a panel of biomarkers may correlate more reliably with fibromyalgia than a single protein (Bazzichi et al., 2009) . In this work we used two-dimensional electrophoresis (2-DE) to obtain the whole saliva protein map of fibromyalgia patients. Figure 1 shows the typical protein pattern obtained from a healthy control subject (figure 1 A) and a fibromyalgia patient (figure 1 B) . Matrix-assisted laser desorption ionization time-of-flight/ time-of-flight mass spectrometry (MALDI-TOF/TOF MS) was used to identify proteins that we found differentially expressed from two analysed groups. In table 3, we report the most interesting proteins which emerged from the data analysis. Table 3 . Protein identification of differentially expressed proteins in whole saliva of fibromyalgia patients by MS/MS Figure 2 shows the enlarged images of these proteins, histograms show the percentage volumes of the proteins and each bar represents the mean±SD of the mean of each spot. Significant differences from control whole saliva are based on Mann-Whitney test; (*p<0.05, **p<0.01, ***p<0.001). Cyclophilin A resulted over-expressed in fibromyalgia patients in comparison with healthy subjects. Cyclophilin A is a ubiquitously distributed protein belonging to the immunophilin family that can be secreted by cells in response to inflammatory stimuli (Arora et al., 2005) . Secreted Cyclophilin A is a potent chemo attractant for monocytes, neutrophils, eosinophils and T cells in vitro. Satoh K and co-workers showed that Cyclophilin A is secreted from smooth muscle cells and macrophages also in response to oxidative stress (Satoh et al., 2008) .
Other proteins found to be over expressed in fibromyalgia were calgranulins, belonging to the S100 multigene family implicated in a variety of intracellular activities such as cell proliferation and differentiation, cytoskeletal interactions, rearrangement and structural organization of membranes, intracellular Ca2+ homeostasis, cell migration, inflammation, and protection from oxidative cell damage (Yang et al., 2001 ). These proteins have already been found in autoinflammatory rheumatic diseases such as Sjögren Syndrome, Scleroderma, and Rheumatoid Arthritis (De Seny et al., 2008; Giusti et al., 2007a Giusti et al., , 2007b Giusti et al., , 2010 . Considering that fibromyalgia is defined as a non-inflammatory disease, we suggested that the over-expression of calgranulins might be related to a sub-inflammatory process, as suggested by the cytokine alterations.
The main finding of our work was the significant over-expression of transaldolase and phosphoglycerate mutase 1 in fibromyalgia patients with respect to controls. The reliability of these potential biomarkers was assessed by receiver operating characteristic curves (figure 3). The sensitivity and the specificity of the transaldolase and phosphoglycerate mutase 1 were 77.3 and 84.6% and 95.5 and 50%, respectively. Furthermore, we validated the results by western blot analysis (figure 4). The statistical analysis of the optical density of specific detected bands confirmed the significant upregulation of two enzymes in fibromyalgia patients with respect to controls. Transaldolase is an enzyme of the non-oxidative phase of the pentose phosphate pathway, which is involved in the generation of reduced nicotinamide adenine dinucleotide phosphate (NADPH). There is a lot of evidence have shown that oxidative stress and nitric oxide may play an important role in fibromyalgia pathophysiology (Ozgocmen et al., 2006) .
The overexpression of transaldolase might be justified by the NADPH production, which could be involved in limiting oxidative damage to tissues. Moreover, transaldolase links the pentose phosphate pathway to glycolysis. From this point of view, it is interesting to note that phosphoglycerate mutase 1, an enzyme involved in glycolysis, was differently expressed in fibromyalgia patients. In conclusion, our study has attested the potential usefulness of the proteomic characterization of human whole saliva in distinguishing fibromyalgia from healthy subjects. Moreover, the use of saliva may enable the easy characterization of non-invasively collected biological fluids, giving rise to a different approach in the diagnosis of fibromyalgia. The future focus of interest will be to validate the panel of biomarkers in different cohorts of pathological controls in order to identify biomarkers specific to fibromyalgia, and to exclude any interference of concomitant disorder (e.g. psychiatric comorbidities). However, this study allows us to focus on some of the peculiar pathogenic aspects of fibromyalgia, especially on the oxidative stress which contradistinguishes this condition.
Conclusion
The pathogenesis of fibromyalgia is not entirely understood and, at present, the diagnosis is only clinical. Up to now, no objective measures have been determined to be reliable biomarkers, and these measures can only reflect a predisposition to fibromyalgia. However, the different studies offer us insights into the pathophysiology of fibromyalgia. The proteomic analysis, rather than the gene expression profile, might have potential applications as a new tool for the diagnosis of fibromyalgia because proteins are the final effectors that mediate disease pathogenesis. Therefore, proteomic seems to represent a necessary element in the advancement of disease diagnosis and therapeutic targets.
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